Page 184 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman

Chapter 9b
neoplasia (TOPIC)-3 study’ is a multicenter, open-label, non-randomized, controlled study, evaluating treatment efficacy, side effects and quality of life associated with imiquimod treatment of high-grade CIN lesions in a selected population of women who prefer imiquimod treatment instead of LLETZ. The study also aims to develop a biomarker profile to predict clinical response to imiquimod treatment. This enables selection of patients in which good treatment response is expected. The study was approved by the Medical Ethics Committee AZM/UM (approval number METC162025) and has been registered on ClinicalTrials.gov (ClinicalTrials.gov Identifier:NCT02917746, 16 September 2016). The study started recruiting patients in November 2016.
182